Improving Clinician and Patient Adherence to Guideline-Recommended Antiplatelet Therapy in ACS: An Interactive Serial-Learning Initiative for Managed Care

Improving Clinician and Patient Adherence to Guideline-Recommended Antiplatelet Therapy in ACS: An Interactive Serial-Learning Initiative for Managed Care—Case Vignettes

Case Vignettes

Jointly sponsored by North American Center for Continuing Medical Education, LLC and Horizon CME

Faculty

Christopher Cannon, MD
Senior Investigator, TIMI Study Group/Brigham & Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Associate Physician
Cardiovascular Division, Brigham & Women’s Hospital
Boston, Massachusetts

Ty J. Gluckman, MD, FACC
Director, Coronary Care Unit
Providence St. Vincent Heart & Vascular Institute
Portland, Oregon

Learning Objectives

After completing this activity, participants should be able to:

Outline the guideline-based role of antiplatelet therapy in the prevention of coronary attacks in patients with acute coronary syndromes (ACS)
Summarize the clinical profiles of current and emerging antiplatelet therapies
Describe the cost-effectiveness of antiplatelet therapy in patients with ACS
Identify barriers to clinician and patient adherence to guideline-based antiplatelet therapy and implement strategies to overcome them

Target Audience

This activity is designed for managed markets physicians and pharmacists.

Activity Overview

This on-demand case vignette series consists of 4 patient case studies, with polling questions integrated throughout each case.

To be eligible for documentation of credit, participants must review each case study, answer all polling questions, complete the 5-question online post-test with a score of 60% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

Release Date: April 26, 2010

Expiration Date: April 26, 2011

Estimated time to complete: 1.5 hours

This educational activity is an application-based activity.

For questions regarding this activity, please call 609-371-1137

Hardware/Software Requirements

All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

CME Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of North American Center for Continuing Medical Education, LLC (NACCME) and Horizon CME. NACCME is accredited by the ACCME to provide continuing medical education for physicians.

NACCME designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CPE Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education (UAN 276-999-10-016-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Luis Gruberg, MD, FACC, Director, Cardiac Catheterization Laboratories, Professor of Medicine, Division of Cardiology, Stony Brook University, Stony Brook, New York

Planning Committee

The planning committee comprises Christopher Cannon, MD, Ty J. Gluckman, MD, FACC, Luis Gruberg, MD, FACC; Elizabeth Hill, Brian Lee, PharmD, Horizon CME; Kristin Dickie, Mary Johnson, Mike Kearney, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:
Dr. Cannon: Grant/research support—Accumetrics, AstaZeneca, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, GlaxoSmithKline, Intekrin Therapeutics, Merck & Co, Inc, Novartis, Takeda Pharmaceuticals North American, Inc; Clinical advisor—Automedics Medical Systems
Dr. Gluckman: Promotional speakers bureau—Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Eli Lilly/Daiichi Sankyo Partnership
Dr. Gruberg: Promotional speakers bureau—Abbott, Eli Lilly and Company

Ms. Dickie, Ms. Hill, Ms. Johnson, Mr. Kearney, Dr. Lee, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that the following off-label/unapproved use(s) of drugs and/or devices will be discussed: The use of ticagrelor, elinogrel (PRT060128), SCH 530348, E5555, and terutroban (S18886) in the treatment of ACS.

Privacy Policy

NACCME and Horizon CME protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME, Horizon CME, and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Horizon CME maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2010 by North American Center for Continuing Medical Education, LLC and Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education and Horizon CME.

Grant Support

Supported by an educational grant from Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership